Send your comments and tips to whitecoat@globe.com
  Awards Beth Israel Deaconess Medical Ctr. Boston Medical Center Boston University Brigham and Women's Hospital Broad Institute Cambridge Health Alliance Caritas St. Elizabeth's Medical Ctr. Children's Hospital Boston Dana-Farber Cancer Institute Grants Harvard University Joslin Diabetes Center Lahey Clinic Mass. General Hospital Mass. Health Law McLean Hospital MIT New England Baptist Hospital Personnel Moves Public Health Research Short White Coat Tufts-New England Medical Center Tufts University UMass Memorial Medical Center University of Massachusetts VA Medical Centers    A Healthy Blog Running A Hospital Nature Network Boston SciBos - Corie Lok's blog Kevin, M.D. Blog, MD Nurse at small Dr. Gwenn Is In Healthy Children blog WBUR's CommonHealth Other Globe Blogs
Elizabeth Cooney is a health reporter for the Worcester Telegram &
Gazette.
Boston Globe Health and Science staff:
Scott Allen Alice Dembner Carey Goldberg Liz Kowalczyk Stephen Smith Colin Nickerson Beth Daley Karen Weintraub, Deputy Health and Science Editor, and Gideon Gil, Health and Science Editor. Short White Coat blogger Ishani Ganguli Short White Coat blogger Jennifer Srygley  Week of:
November 11
Week of:
November 4
Week of:
October 28
Week of:
October 21
Week of:
October 14
Week of:
October 7
|
« Short White Coat: Let the games begin | Main | Psychiatrists, children and drug industry's role » Thursday, May 10, 2007Today's Globe: healthcare fees, HPV and throat cancer, FDA drug-review revamp, life sciences betTaxpayers are bearing a larger share of the cost of the expansion of healthcare coverage than expected because the state has not yet collected a penny from businesses that do not help insure their workers. The sexually transmitted virus that causes cervical cancer also sharply increases the risk of certain types of throat cancer among people infected through oral sex, according to a study about the human papillomavirus, or HPV, being published today. The Food and Drug Administration would have to establish a system to monitor the safety of new drugs after they hit the market and the pharmaceutical industry would be required to register clinical trials of new medicines in a publicly available database under legislation approved yesterday by the Senate. The Patrick administration's proposal to stimulate the life sciences sector here by investing $1 billion in public funds over 10 years is a bold effort to insulate the state against flat federal funding for biomedical research and fend off competitors, including California and North Carolina, that threaten Massachusetts' dominant position in the industry, a Globe editorial says. Posted by Elizabeth Cooney at 06:21 AM
|
